A Pilot Study of Short (1-2.5 h), Medium (4-6 h) and Long (18-24 h) Applications of 20% Topical ALA-PDT for Photodynamic Therapy of Cutaneous T and B Cell Lymphomas and Cutaneous Infiltrates of Early CLL
- Determine the pain grade and epidermal toxic response (ETR) of patients with T-cell or
B-cell lymphoma or early chronic lymphocytic leukemia with cutaneous infiltrates
treated with photodynamic therapy using aminolevulinic acid.
- Determine the feasibility of maintaining a pain grade of 1 or less and an approximate
ETR of 2 in patients receiving up to 12 sessions of this regimen.
- Determine the maximal irradiance and corresponding exposure among multiple treatments
at the same site and among different sites in the same and in different patients.
- Determine the cumulative response achieved at the completion of treatment in these
- Determine the number of sessions required to complete treatment in these patients.
- Correlate ETR with incremental treatment response in patients treated with this
OUTLINE: This is a randomized study. Patients' individual lesions are randomized to 1 of 3
- Arm I: Patients receive a short duration of topical aminolevulinic acid (ALA) on the
lesion and surrounding normal skin. The lesion is then illuminated with red light for
up to 30 minutes.
- Arm II: Patients receive a medium duration of ALA followed by light illumination as in
- Arm III: Patients receive a long duration of ALA followed by light illumination as in
In all arms, treatment repeats every 2 weeks for up to 12 courses in the absence of
unacceptable toxicity or progressive (systemic) disease.
Additional patients are accrued to a treatment arm if at least 2 of 3 patients on that arm
experience 25% cumulative clinical response.
Patients are followed at 1, 3, and 6 months and then every 6 months for 2 years.
PROJECTED ACCRUAL: A total of 4-10 patients will be accrued for this study within 5-7 years.
Allocation: Randomized, Primary Purpose: Treatment
Pain grade and epidermal toxic response (ETR)
Allan R. Oseroff, MD, PhD
Roswell Park Cancer Institute
United States: Food and Drug Administration
|Roswell Park Cancer Institute||Buffalo, New York 14263|